马来酸桂哌齐特注射剂治疗急性缺血性脑卒中有效性的分析

发布时间：2018-02-03 11:10

本文关键词： 马来酸桂哌齐特急性缺血性脑卒中 Meta分析有效性　出处：《中国临床药理学杂志》2017年20期 　论文类型：期刊论文

【摘要】：目的系统评价马来酸桂哌齐特治疗急性缺血性脑卒中的有效性。方法检索Pub Med、Em Base、Cochrane图书馆临床对照试验资料库、Clinical Trials和中国知网、万方、维普、中国生物医学文献数据库,截至2016年9月。用Rev Man 5.3软件,对美国国立卫生研究院卒中量表(NIHSS)评分改善情况、临床有效率进行统计分析。试验组为马来酸桂哌齐特联合基础治疗,对照组为空白或其他脑神经保护类西药注射剂或脑神经保护类中药注射剂联合基础治疗。结果共纳入20个随机对照研究,涉及急性缺血性脑卒中患者2237例。Meta分析结果:试验组比对照组治疗后NIHSS评分多降低2.73,试验组临床有效率是对照组的1.22倍,差异均有统计学意义(均P0.01)。结论马来酸桂哌齐特能降低急性缺血性脑卒中患者NIHSS评分,提高临床有效率。
[Abstract]:Objective to evaluate the efficacy of cinepazide maleate in the treatment of acute ischemic stroke. Methods the clinical controlled trial database of Pub MedmBaseCochrane Library was searched. Clinical Trials and China Zhiwang, Wanfang, Weipu, China Biomedical Literature Database, as of September 2016. Rev Man 5.3 software. The improvement of NIHSS score in the National Institutes of Health (NIH) and the clinical effective rate were statistically analyzed. The trial group was treated with cinepazide maleate combined with basic therapy. The control group was treated with blank or other cerebral neuroprotective medicine injection or traditional Chinese medicine injection. Results 20 randomized controlled studies were conducted. Meta-analysis of 2237 patients with acute ischemic stroke: the NIHSS score in the trial group was 2.73 lower than that in the control group after treatment. The clinical effective rate in the trial group was 1.22 times of that in the control group, and the difference was statistically significant (all P 0.01). Conclusion Cinepazide maleate can reduce the NIHSS score of patients with acute ischemic stroke. Improve the clinical effective rate.
【作者单位】：北京大学第三医院药剂科;北京大学药学院药事管理与临床药学系;北京大学医学部药物评价中心;
【分类号】：R743.3
【正文快照】： (1.北京大学第三医院药剂科,北京100191;2.北京大学药学院药事管理与临床药学系,北京100191;3.北京大学医学部药物评价中心,北京100191)ZHU Si-yuan1,2,3,YAN Ying-ying1,3,YI Zhan-miao1,3,ZHAI Suo-di1,2,3(1.Department of Pharmacy,PekingUniversity Third hospital,Beiji

【相似文献】